Polymeric micelle nanocarriers for targeted epidermal delivery of the hedgehog pathway inhibitor vismodegib: formulation development and cutaneous biodistribution in human skin

References

• Gould SE, Low JA, Marsters JC, et al. Discovery and preclinical development of vismodegib. Expert Opin Drug Discov. 2014;9:969–984.
   PubMed Web of Science ®Google Scholar
• Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272:1668–1671.
   PubMed Web of Science ®Google Scholar
• Hahn H, Wicking C, Zaphiropoulos PG, et al. Mutations of the human homolog of drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841–851.
   PubMed Web of Science ®Google Scholar
• Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–1080.
   PubMed Web of Science ®Google Scholar
• Rogers HW, Weinstock MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151:1081–1086.
   PubMed Web of Science ®Google Scholar
• Soura E, Chasapi V, Stratigos AJ. Pharmacologic treatment options for advanced epithelial skin cancer. Expert Opin Pharmacother. 2015;16:1479–1493.
   PubMed Web of Science ®Google Scholar
• Macha MA, Batra SK, Ganti AK. Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma. Cancer Manag Res. 2013;5:197–203.
   PubMedGoogle Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–2179.
   PubMed Web of Science ®Google Scholar
• Proctor AE, Thompson LA, O’Bryant CL. Vismodegib: an inhibitor of the hedgehog signaling pathway in the treatment of basal cell carcinoma. Ann Pharmacother. 2013;48:99–106.
   PubMed Web of Science ®Google Scholar
• ERIVEDGE® (vismodegib) capsule for oral use. USA: USFDA; 2012 [cited 2018 Aug 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf
   Google Scholar
• Micali G, Lacarrubba F, Bhatt K, et al. Medical approaches to non-melanoma skin cancer. Expert Rev Anticancer Ther. 2013;13:1409–1421.
   PubMed Web of Science ®Google Scholar
• Paola S, Ottavio C, Paolo F. New perspectives in the pharmacological treatment of non-melanoma skin cancer. Curr Drug Targets. 2016;17:353–374.
   PubMed Web of Science ®Google Scholar
• Wiechers JW, Kelly CL, Blease TG, et al. Formulating for efficacy 1. Int J Cosmet Sci. 2004;26:173–182.
   PubMedGoogle Scholar
• Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release. 2012;159:14–26.
   PubMed Web of Science ®Google Scholar
• Lazzeroni M, Serrano D, Dunn BK, et al. Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Res. 2012;14:214.
   PubMed Web of Science ®Google Scholar
• Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev. 2002;54:169–190.
   PubMed Web of Science ®Google Scholar
• Bachhav YG, Mondon K, Kalia YN, et al. Novel micelle formulations to increase cutaneous bioavailability of azole antifungals. J Control Release. 2011;153:126–132.
   PubMed Web of Science ®Google Scholar
• Lapteva M, Mondon K, Moller M, et al. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Mol Pharm. 2014;11:2989–3001.
   PubMed Web of Science ®Google Scholar
• Lapteva M, Santer V, Mondon K, et al. Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways. J Control Release. 2014;196:9–18.
   PubMed Web of Science ®Google Scholar
• Gabriel D, Mugnier T, Courthion H, et al. Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis. J Control Release. 2016;242:16–24.
   PubMed Web of Science ®Google Scholar
• Mondon K, Zeisser-Labouèbe M, Gurny R, et al. Novel cyclosporin A formulations using MPEG–hexyl-substituted polylactide micelles: A suitability study. Eur J Pharm Biopharm. 2011;77:56–65.
   PubMed Web of Science ®Google Scholar
• Lapteva M, Moller M, Gurny R, et al. Self-assembled polymeric nanocarriers for the targeted delivery of retinoic acid to the hair follicle. Nanoscale. 2015;7:18651–18662.
   PubMed Web of Science ®Google Scholar
• OECD Guideline for the testing of chemicals. Skin absorption: in vitro method. OECD; 2004 [cited 2017 Feb 06]. Available from: http://www.oecd-ilibrary.org/environment/test-no-428-skin-absorption-in-vitro-method_9789264071087-en
   Google Scholar
• Papakostas D, Rancan F, Sterry W, et al. Nanoparticles in dermatology. Arch Dermatol Res. 2011;303:533–550.
   PubMed Web of Science ®Google Scholar
• Rijcken CJF, Soga O, Hennink WE, et al. Triggered destabilisation of polymeric micelles and vesicles by changing polymers polarity: an attractive tool for drug delivery. J Control Release. 2007;120:131–148.
   PubMed Web of Science ®Google Scholar
• Owen SC, Chan DPY, Shoichet MS. Polymeric micelle stability. Nano Today. 2012;7:53–65.
   Web of Science ®Google Scholar
• Herkenne C, Naik A, Kalia YN, et al. Pig ear skin ex vivo as a model for in vivo dermatopharmacokinetic studies in man. Pharm Res. 2006;23:1850–1856.
   PubMed Web of Science ®Google Scholar
• Sekkat N, Kalia YN, Guy RH. Biophysical study of porcine ear skin in vitro and its comparison to human skin in vivo. J Pharm Sci. 2002;91:2376–2381.
   PubMed Web of Science ®Google Scholar
• Schmook FP, Meingassner JG, Billich A. Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int J Pharm. 2001;215:51–56.
   PubMed Web of Science ®Google Scholar
• Dick IP, Scott RC. Pig ear skin as an in-vitro model for human skin permeability. J Pharm Pharmacol. 1992;44:640–645.
   PubMed Web of Science ®Google Scholar
• Jacobi U, Kaiser M, Toll R, et al. Porcine ear skin: an in vitro model for human skin. Skin Res Technol. 2007;13:19–24.
   PubMed Web of Science ®Google Scholar
• Scales SJ, de Sauvage FJ. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009;30:303–312.
   PubMed Web of Science ®Google Scholar
• Nguyen HX, Banga AK. Enhanced skin delivery of vismodegib by microneedle treatment. Drug Deliv Transl Res. 2015;5:407–423.
   PubMed Web of Science ®Google Scholar
• Christensen E, Mjønes P, Grimstad Ø, et al. Comparison of clinical and histopathological evaluations of basal cell carcinoma thickness. Br J Dermatol. 2015;173:578–580.
   PubMed Web of Science ®Google Scholar
• Foss OA, Mjønes P, Fismen S, et al. Is there a relationship between the stratum corneum thickness and that of the viable parts of tumour cells in basal cell carcinoma? J Skin Cancer. 2016;2016:6146091.
   PubMedGoogle Scholar
• McKay KM, Sambrano BL, Fox PS, et al. Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of sBCC. Br J Dermatol. 2013;169:549–554.
   PubMed Web of Science ®Google Scholar